Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Deals are abound!!!!

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Aug 05, 2022 1:15pm

169 Views

Post# 34874629

RE:RE:Deals are abound!!!!

Exactly !!!
it is all very intersting to see Roche's direction with all these areas that seem to surround Pela's ability to make all of thier directions work better.

That is why I am personally thinking Roche will step up. But only time will tell.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market